Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals
暂无分享,去创建一个
Jerome H. Kim | Zhi Wei | R. Koup | M. Robb | R. Bailer | N. Michael | M. Eller | J. Currier | H. Kibuuka | M. Marovich | S. Ratto-Kim | Yu Zhou | Haitao Hu | Mengnan Gu | Shahnilah Zafar
[1] Eric Hunter,et al. Immune Activation with HIV Vaccines , 2014, Science.
[2] R. Cortese,et al. Adenovirus Type 4 and 7 Vaccination or Adenovirus Type 4 Respiratory Infection Elicits Minimal Cross-Reactive Antibody Responses to Nonhuman Adenovirus Vaccine Vectors , 2014, Clinical and Vaccine Immunology.
[3] Holly Janes,et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.
[4] C. Hoke,et al. History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. , 2013, Vaccine.
[5] Jerome H. Kim,et al. Distinct gene expression profiles associated with the susceptibility of pathogen-specific CD4+ T cells to HIV-1 infection , 2012, Retrovirology.
[6] S. Buchbinder,et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). , 2012, The Journal of infectious diseases.
[7] Allan C. deCamp,et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. , 2012, The Journal of clinical investigation.
[8] J. Shiver,et al. Low-Dose Penile SIVmac251 Exposure of Rhesus Macaques Infected with Adenovirus Type 5 (Ad5) and Then Immunized with a Replication-Defective Ad5-Based SIV gag/pol/nef Vaccine Recapitulates the Results of the Phase IIb Step Trial of a Similar HIV-1 Vaccine , 2011, Journal of Virology.
[9] J. Kublin,et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. , 2011, The Lancet. Infectious diseases.
[10] Matthew S. Lewis,et al. Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.
[11] R. Koup,et al. Preferential infection and depletion of Mycobacterium tuberculosis–specific CD4 T cells after HIV-1 infection , 2010, The Journal of experimental medicine.
[12] Jerome H. Kim,et al. Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate , 2010, PloS one.
[13] D. Barouch. Novel adenovirus vector-based vaccines for HIV-1 , 2010, Current opinion in HIV and AIDS.
[14] K. Mansfield,et al. Mucosal Trafficking of Vector-Specific CD4+ T Lymphocytes following Vaccination of Rhesus Monkeys with Adenovirus Serotype 5 , 2010, Journal of Virology.
[15] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[16] G. Dickson,et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 , 2009, Proceedings of the National Academy of Sciences.
[17] Mario Roederer,et al. Autocrine Production of β-Chemokines Protects CMV-Specific CD4+ T Cells from HIV Infection , 2009, PLoS pathogens.
[18] S. Pambuccian,et al. Glycerol monolaurate prevents mucosal SIV transmission , 2009, Nature.
[19] Devan V Mehrotra,et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.
[20] G. Lewis,et al. ‘Self-Protection’ of Individual CD4+ T Cells against R5 HIV-1 Infection by the Synthesis of Anti-Viral CCR5 Ligands , 2008, PloS one.
[21] D. Douek,et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. , 2008, Blood.
[22] A. Garzino-Demo,et al. Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection. , 2007, Virology.
[23] M. Robb,et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. , 2007, Vaccine.
[24] Kenneth H Mayer,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.
[25] D. Price,et al. CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.
[26] David Montefiori,et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] L. Gooding,et al. Prevalence and Quantitation of Species C Adenovirus DNA in Human Mucosal Lymphocytes , 2002, Journal of Virology.
[28] Henryk Mach,et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.